AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies-Reference-Cited by-同舟云学术

AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies

Published:2018-09-25 Issue: Volume: Page:CD-18-0387
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Caenepeel Sean,Brown Sean P^ORCID,Belmontes Brian,Moody Gordon,Keegan Kathleen S,Chui Danny,Whittington Douglas A.,Huang Xin,Poppe Leszek,Cheng Alan C.,Cardozo Mario,Houze Jonathan,Li Yunxiao,Lucas Brian,Paras Nick A.^ORCID,Wang Xianghong,Taygerly Joshua P,Vimolratana Marc,Zancanella Manuel,Zhu Liusheng,Cajulis Elaina,Osgood Tao,Sun Jan,Damon Leah^ORCID,Egan Regina K.,Greninger Patricia^ORCID,McClanaghan Joseph D,Gong Jianan,Moujalled Donia,Pomilio Giovanna,Beltran Pedro,Benes Cyril H.^ORCID,Roberts Andrew W.^ORCID,Huang David C.S.^ORCID,Wei Andrew,Canon Jude,Coxon Angela,Hughes Paul E.

Funder

Amgen (Amgen Inc.)

Australian Cancer Research Foundation (ACRF)

Department of Health | National Health and Medical Research Council (NHMRC)

Independent Research Institutes

The Cancer Council Victoria

Leukemia and Lymphoma Society (LLS)

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 296 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Potent Mcl-1 Inhibitors: Structural Investigations on Macrocycles Originating from a DNA-Encoded Chemical Library Screen;Journal of Medicinal Chemistry;2024-02-02

2. Apoptosis Inhibitor 5: A Multifaceted Regulator of Cell Fate;Biomolecules;2024-01-22

3. Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?;Journal of Clinical Medicine;2024-01-18

4. Mcl-1 Protein and Viral Infections: A Narrative Review;International Journal of Molecular Sciences;2024-01-17

5. The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma;Cancers;2023-12-13